Austin Institute for Clinical Research

Austin Institute for Clinical Research has an active portfolio of industry-sponsored dermatology clinical trials across multiple indications including atopic dermatitis, psoriasis, urticaria, alopecia areata, and vitiligo. The company partners with pharmaceutical sponsors to conduct high-quality studies focused on patient safety and retention. Recent studies include those evaluating ritlecitinib for vitiligo, pegylated-recombinant therapies for skin conditions, barzolvolimab and EVO756 for urticaria subtypes, apremilast in pediatric populations with psoriasis/dermatitis-related conditions, baricitinib in alopecia areata and plaque psoriasis patients with obesity or overweight status; lebrikizumab in moderate-to-severe atopic dermatitis; guselkumab in skin-of-color participants with moderate-to-severe plaque psoriasis; abrocitinib plus topical medications; photodynamic therapy using Ameluz®; among others.